Solutions
Digital Cognitive Assessment
Endpoint Data Quality (Rater Services)
Remote Assessment
Scientific Consulting
Healthcare Cognitive Screening
Research and Academic Collaborations
Therapeutic Expertise
Alzheimer’s Disease and Dementia
Preclinical Alzheimer’s Disease
Pediatrics & Rare Disease
Parkinson’s Disease
Multiple Sclerosis
Schizophrenia
Oncology
Safety
Resources
Fact Sheets
Webinars
Posters
Publications
Blog
Company
About Cogstate
Leadership Teams
Clinical & Scientific Network (LEADs)
Company News
Careers & Life at Cogstate
CTAD 2023
Investor Centre
Corporate Governance
Board of Directors
ASX Announcements & Share Price
Financial Reports
Investor Presentations
Financial Calendar
Shareholder Information
Contact Us
Support
Solutions
Digital Cognitive Assessment
Endpoint Data Quality (Rater Services)
Remote Assessment
Scientific Consulting
Healthcare Cognitive Screening
Research and Academic Collaborations
Therapeutic Expertise
Alzheimer’s Disease and Dementia
Preclinical Alzheimer’s Disease
Pediatrics & Rare Disease
Parkinson’s Disease
Multiple Sclerosis
Schizophrenia
Oncology
Safety
Resources
Fact Sheets
Webinars
Posters
Publications
Blog
Company
About Cogstate
Leadership Teams
Clinical & Scientific Network (LEADs)
Company News
Careers & Life at Cogstate
CTAD 2023
Investor Centre
Corporate Governance
Board of Directors
ASX Announcements & Share Price
Financial Reports
Investor Presentations
Financial Calendar
Shareholder Information
Contact Us
Support
The Cogstate Blog
Gather insights and guidance from the experts in cognitive measurement.
Search
Show All
September 12, 2023
2,000 Preclinical Alzheimer’s Cognitive Composite (PACC) Administrations: Common Rater Errors + Tips for Preclinical AD Trials
September 12, 2023
Preclinical Alzheimer’s Cognitive Composite (PACC): Validated Digital Option Reduces Burden for Patients and Clinical Trial Teams
September 5, 2023
Cogstate CBB: Sensitivity to Cognitive Impairment and Connection to Alzheimer’s Disease Biomarkers
August 29, 2023
From Donepezil to Today | Reflections from 20+ Years on the Front Line of Alzheimer’s Disease Science
April 6, 2023
Digit Symbol Substitution Test (DSST): New Digital Version is Sensitive and Low-burden Option for Global Alzheimer’s Disease Trials
January 25, 2023
Momentum in Alzheimer’s Disease Research | Scientific and Operational Advancements in Clinical Trials
September 20, 2022
Evaluating Cognition in Parkinson’s Disease Clinical Trials: 5 Scale Selection Questions
September 12, 2022
Central Rating — Benefits and Considerations for CNS Clinical Outcome Assessment
August 23, 2022
Building and Identifying Clinically Relevant Change Across the Alzheimer’s Disease Spectrum
March 1, 2022
Behavioral and Biological Markers in Rare Disease Research: Tandem Approach Increases Sensitivity and Specificity
April 27, 2021
Parkinson’s Disease Clinical Trial Services and Resources
March 31, 2021
A New Clinical Global Impression Scale Enables Precise Detection of Severity and Improvement in Angelman Syndrome
March 16, 2021
Clinical Dementia Rating–Sum of Boxes: A Promising Outcome Measure for Improved Sensitivity to Treatment Efficacy in Future AD Clinical Trials
February 8, 2021
Researchers Share Cognitive Go/No-Go Decision-Making Criteria for Alzheimer’s Disease Drug Development
September 28, 2020
Study Explored the Preferences of Middle-aged and Older Black Adults Completing Cognitive Testing
How can we help you optimize the measurement of brain health?
Contact Our Team
We use cookies to analyze our website traffic and to support technical features that enhance your user experience. Read our
Privacy
and
Cookie
Policies to learn more about how we use cookies.
Accept Cookies
Decline Cookies